Clinical Trial Update: Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating three dose levels of subcutaneous semaglutide once daily vs placebo in non-alcoholic steatohepatitis; study completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Hepatobiliary Disorders, Non-alcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2021-04-21